Skip to Content
Not all colorectal cancer treatments are the same. Find out more >

Idamycin (idarubicin) Disease Interactions

There are 6 disease interactions with Idamycin (idarubicin):

Major

Antineoplastics (Includes Idamycin) ↔ Infections

Severe Potential Hazard, High plausibility

Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  3. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
View all 31 references
Major

Idarubicin (Includes Idamycin) ↔ Heart Disease

Severe Potential Hazard, High plausibility

Applies to: Congestive Heart Failure, Heart Disease

Idarubicin can cause myocardial toxicity leading to congestive heart failure. Patients with preexisting heart disease or prior anthracycline therapy are at increased risk of congestive heart failure. Close clinical monitoring of cardiac function, such as an electrocardiogram and/or determination of left ventricular ejection fraction, prior to each course of therapy is recommended.

References

  1. Chan-Lam D, Copplestone JA, Prentice A, Price R, Johnson S, Phillips M "Idarubicin cardiotoxicity in acute myeloid leukaemia." Lancet 340 (1992): 185-6
  2. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  3. Bertelli G, Amoroso D, Pronzato P, Rosso R "Idarubicin: an evaluation of cardiac toxicity in 77 patients with solid tumors." Anticancer Res 8 (1988): 645-6
View all 5 references
Major

Idarubicin (Includes Idamycin) ↔ Hepatic Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Idarubicin undergoes extensive extrahepatic metabolism and is primarily eliminated by biliary excretion. The pharmacokinetic disposition of idarubicin has not been studied in leukemia patients with hepatic impairment. It is thought that the metabolism of idarubicin would be decreased in moderate to severe hepatic dysfunction and lead to increased systemic drug levels and toxicity. Therapy with idarubicin should be administered cautiously and dosage reduction considered in patients with compromised hepatic function. Idarubicin injection should not be administered if bilirubin level exceeds 5 mg %.Clinical monitoring of hepatic function is recommended prior to and during therapy.

References

  1. Petti MC, Mandelli F "Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA." Semin Oncol 16 (1 Suppl) (1989): 10-5
  2. Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, et al "Phase I and II clinical and pharmacological study of 4- demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia." Cancer Res 45 (1985): 1408-12
  3. Dodion P, Finet C, Crespeigne N, Beer M, Nicaise C, Rozencweig M, Kenis Y "Phase I study of oral idarubicin given with a weekly schedule." Invest New Drugs 4 (1986): 31-8
View all 7 references
Major

Idarubicin (Includes Idamycin) ↔ Myelosuppression

Severe Potential Hazard, High plausibility

Applies to: Bone Marrow Depression/Low Blood Counts, Bleeding, Fever, Infection - Bacterial/Fungal/Protozoal/Viral

Idarubicin induces severe myelosuppression at therapeutic doses. Therapy with idarubicin should be withheld in patients whose bone marrow function is severely depressed by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. If the need outweighs the risk, extreme caution should be exercised in administering idarubicin. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression such as fever, sore throat, local infection, or bleeding. Close clinical monitory of hematopoietic function is recommended.

References

  1. Daghestani AN, Arlin ZA, Leyland-Jones B, Gee TS, Kempin SJ, Mertelsmann R, Budman D, Schulman P, Baratz R, Williams L, et al "Phase I and II clinical and pharmacological study of 4- demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia." Cancer Res 45 (1985): 1408-12
  2. Ganzina F, Pacciarini MA, Di Pietro N "Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies." Invest New Drugs 4 (1986): 85-105
  3. Petti MC, Mandelli F "Idarubicin in acute leukemias: experience of the Italian Cooperative Group GIMEMA." Semin Oncol 16 (1 Suppl) (1989): 10-5
View all 11 references
Major

Idarubicin (Includes Idamycin) ↔ Renal Dysfunction

Severe Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Impaired renal function can affect the disposition of idarubicin. Therapy with idarubicin should be administered cautiously and dosage modification considered in patients with compromised renal function. Clinical monitoring of renal function is recommended prior to and during therapy.

References

  1. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
Moderate

Idarubicin (Includes Idamycin) ↔ Hyperuricemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperuricemia Secondary to Chemotherapy

Treatment with idarubicin may cause hyperuricemia as a result of rapid lysis of tumor cells. Levels of serum uric acid should be monitored and appropriate therapy should be initiated before starting therapy.

Idamycin (idarubicin) drug Interactions

There are 410 drug interactions with Idamycin (idarubicin)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2017 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide